{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:33:37Z","timestamp":1793032417176,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81860302"],"award-info":[{"award-number":["81860302"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.crad.2023.10.011","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T04:50:37Z","timestamp":1698555037000},"page":"e264-e272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Relationships between intravoxel incoherent motion parameters and expressions of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in patients with cervical cancer"],"prefix":"10.1016","volume":"79","author":[{"given":"K.H.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.P.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.crad.2023.10.011_bib1","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1002\/cncr.33795","article-title":"Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years","volume":"127","author":"Lin","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.crad.2023.10.011_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.6004\/jnccn.2019.0001","article-title":"Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Koh","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.crad.2023.10.011_bib3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00330-019-06428-w","article-title":"Multiparametric PET\/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumor recurrence in patients with locally advanced cervical cancer","volume":"30","author":"Gao","year":"2020","journal-title":"Eur Radiol"},{"key":"10.1016\/j.crad.2023.10.011_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.crad.2023.10.011_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12032-022-01646-7","article-title":"Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer","volume":"39","author":"Bose","year":"2022","journal-title":"Med Oncol"},{"key":"10.1016\/j.crad.2023.10.011_bib6","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.crad.2023.10.011_bib7","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.crad.2023.10.011_bib8","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.crad.2023.10.011_bib9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crad.2023.10.011_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41416-020-0876-9","article-title":"Does multiparametric imaging with (18)F-FDG-PET\/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?","volume":"123","author":"Rasmussen","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.crad.2023.10.011_bib11","doi-asserted-by":"crossref","first-page":"18510","DOI":"10.18632\/oncotarget.24905","article-title":"Histogram analysis of ADC in rectal cancer: associations with different histopathological findings including expression of EGFR, Hif1-alpha, VEGF, p53, PD1, and KI 67. A preliminary study","volume":"9","author":"Meyer","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.crad.2023.10.011_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1148\/radiol.2015150244","article-title":"Clinical intravoxel incoherent motion and diffusion MR imaging: past, present, and future","volume":"278","author":"Iima","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.crad.2023.10.011_bib13","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1007\/s00330-021-07817-w","article-title":"Association between IVIM parameters and treatment response in locally advanced squamous cell cervical cancer treated by chemoradiotherapy","volume":"31","author":"Perucho","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.crad.2023.10.011_bib14","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3390\/jpm12040638","article-title":"Intravoxel incoherent motion (IVIM) MR quantification in locally advanced cervical cancer (LACC): preliminary study on assessment of tumor aggressiveness and response to neoadjuvant chemotherapy","volume":"12","author":"Dolciami","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.crad.2023.10.011_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.mri.2020.06.014","article-title":"Prediction of early response to concurrent chemoradiotherapy in cervical cancer: value of multi-parameter MRI combined with clinical prognostic factors","volume":"72","author":"Zheng","year":"2020","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.crad.2023.10.011_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40644-019-0285-6","article-title":"The value of DWI in predicting the response to synchronous radiochemotherapy for advanced cervical carcinoma: comparison among three mathematical models","volume":"20","author":"Zhang","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.crad.2023.10.011_bib17","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1021\/acs.jmedchem.9b01101","article-title":"Interpretation of compound activity predictions from complex machine learning models using local approximations and Shapley values","volume":"63","author":"Rodr\u00edguez-P\u00e9rez","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.crad.2023.10.011_bib18","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00330-017-4989-3","article-title":"Multi-parametric MRI in cervical cancer: early prediction of response to concurrent chemoradiotherapy in combination with clinical prognostic factors","volume":"28","author":"Yang","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.crad.2023.10.011_bib19","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1007\/s00330-021-08279-w","article-title":"Added-value of dynamic contrast-enhanced MRI on prediction of tumor recurrence in locally advanced cervical cancer treated with chemoradiotherapy","volume":"32","author":"Zhang","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.crad.2023.10.011_bib20","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/jcm8050743","article-title":"Expression of PD-1 and CTLA-4 are negative prognostic markers in renal cell carcinoma","volume":"8","author":"Kahlmeyer","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.crad.2023.10.011_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1413519","article-title":"Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma","volume":"7","author":"Kim","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.crad.2023.10.011_bib22","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/jmri.26604","article-title":"Intravoxel incoherent motion combined with dynamic contrast-enhanced perfusion MRI of early cervical carcinoma: correlations between multimodal parameters and HIF-1\u03b1 expression","volume":"50","author":"Li","year":"2019","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.crad.2023.10.011_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8873065","article-title":"Predictive Ki-67 proliferation index of cervical squamous cell carcinoma based on IVIM-DWI combined with texture features","volume":"2021","author":"Li","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.crad.2023.10.011_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263615","article-title":"Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients","volume":"17","author":"Omenai","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.crad.2023.10.011_bib25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/cancers14030480","article-title":"The clinical, pathological, and prognostic value of high PD-1 expression and the presence of Epstein\u2013Barr virus reactivation in patients with laryngeal cancer","volume":"14","author":"Klatka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.crad.2023.10.011_bib26","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1158\/1078-0432.CCR-09-1652","article-title":"Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma","volume":"15","author":"Karim","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.crad.2023.10.011_bib27","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/jog.13411","article-title":"Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status","volume":"43","author":"Yang","year":"2017","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.crad.2023.10.011_bib28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/DDDT.S75152","article-title":"Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer","volume":"9","author":"Qing","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.crad.2023.10.011_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1215\/15228517-2008-104","article-title":"Regulatory T cells and the PD-L1\/PD-1 pathway mediate immune suppression in malignant human brain tumors","volume":"11","author":"Jacobs","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.crad.2023.10.011_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1 (PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023004580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023004580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T16:50:22Z","timestamp":1757868622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926023004580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0009926023004580"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2023.10.011","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationships between intravoxel incoherent motion parameters and expressions of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) in patients with cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2023.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}